Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine. - Wikidata - awgldk - TriplyDB

Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

http://www.wikidata.org/entity/Q31159398

about

Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1.The dichotomy of pathogens and allergens in vaccination approaches Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge.Effect of AcHERV-GmCSF as an Influenza Virus Vaccine Adjuvant Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens.Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model.

P2860

Q30387699-788FD9D6-FF96-42C0-8311-EE931D33265E Q33909251-F74B94BC-DA8E-48B4-A70E-8E77DE197B66 Q35196568-FF4F9EA2-12E3-4F22-827B-1A69C2137FF9 Q35668481-06063F27-7AEE-411E-B5D4-4EE75E3E8C8E Q38243160-3F75B914-3DAA-4E63-BFAF-3CAC7D26CA6D Q38869506-8A77BB70-D16D-4B37-B0FB-1F8F405293CF Q40129472-4ECA1A3C-52B6-4F74-80CA-314A70E456CD

P2860

Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

http://www.wikidata.org/entity/Q31159398

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Immunogenicity of a trivalent ...... cable baculovirus nanovaccine.

@ast

Immunogenicity of a trivalent ...... cable baculovirus nanovaccine.

@en

type

label

Immunogenicity of a trivalent ...... cable baculovirus nanovaccine.

@ast

Immunogenicity of a trivalent ...... cable baculovirus nanovaccine.

@en

prefLabel

Immunogenicity of a trivalent ...... cable baculovirus nanovaccine.

@ast

Immunogenicity of a trivalent ...... cable baculovirus nanovaccine.

@en

P1433

Q31159398-D9949991-4B8A-4292-B55D-D43C17870F3A

P1476

Q31159398-4DD5C927-61A7-48FD-9242-952D1832E31B

P2093

Q31159398-0A59C0BC-410B-4D34-8653-FB7C4598576B

Q31159398-0E90E1BB-CF18-4279-AD96-89488A4B626F

Q31159398-2B84E2BC-4F80-46AC-BA60-61E83C3BFD9C

Q31159398-37FBAF21-9A0D-477E-B055-72E2273675BD

Q31159398-6AA634DA-9F6A-42E0-923C-ADA6498C23DF

Q31159398-811C7BB4-4289-495C-BA67-825EBFF91F10

Q31159398-E0537CE7-7E96-44FF-BFA2-273547DA6EBE

P2860

Q31159398-03F0AFFF-7C67-4404-BEF0-D670B1C363FE

Q31159398-1712C2A7-E96A-4AC7-9E0D-B8F9622BBA81

Q31159398-18C1D372-8CE6-48DA-ACA0-58334FA693C7

Q31159398-37920437-5013-409F-9B11-325CFC886E81

Q31159398-39075FC6-DF00-4FE8-B0AB-B5B360E107DB

Q31159398-39391BE9-9117-4984-BF87-A489E0C30B2D

Q31159398-398047BD-0FAE-475C-BC82-C12B1BECA30D

Q31159398-3B032C48-777F-4086-BE71-87C5C67A33FB

Q31159398-560D8445-19E5-4097-8055-120E860658EC

Q31159398-65B83355-06E8-45A2-9BC9-1B279445DBE2

P304

Q31159398-CBAF0C03-2594-4263-BBC6-2492D57F0728

P31

Q31159398-71F61773-8C9B-4DED-B558-E45984505229

P356

Q31159398-B0FF172F-1683-41B0-BA02-D4029D0C3E69

P407

Q31159398-B74D6F1F-AC50-47B6-843D-0699A19A0BA6

P433

Q31159398-4EB2AEB3-0C01-4892-B960-AF0B5201F96F

P478

Q31159398-52FAF474-9D75-4F15-B628-9F859489E615

P50

Q31159398-434893C4-752A-4F09-876D-B33B665C92D2

Q31159398-819942F9-52BB-4B4E-90C2-6384AE0EEC9D

P577

Q31159398-22CC9E6F-5063-494B-B217-E5787639432B

P5875

Q31159398-9EBC2690-4DA5-42F7-A463-5D4B94AC9B6C

P698

Q31159398-11D740E7-4A49-45F8-98A9-4C862561FDFE

P932

Q31159398-C679D105-2074-42E5-8BEA-8C1BC7C57766

P356

JOURNAL.PONE.0095961

P1433

P1476

Immunogenicity of a trivalent ...... cable baculovirus nanovaccine.

@en

P2093

Hansam Cho

http://www.w3.org/2001/XMLSchema#string

Hee-Jung Lee

http://www.w3.org/2001/XMLSchema#string

Ki Hoon Park

http://www.w3.org/2001/XMLSchema#string

Mi-Gyeong Kim

http://www.w3.org/2001/XMLSchema#string

Yeondong Cho

http://www.w3.org/2001/XMLSchema#string

Yoon-Ki Heo

http://www.w3.org/2001/XMLSchema#string

Young Bong Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Papillomaviruses and cancer: from basic studies to clinical application

Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009.

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Recombinant baculoviruses as mammalian cell gene-delivery vectors.

Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1

Human papillomaviruses and their role in cervical cancer.

Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.

Improvement of different vaccine delivery systems for cancer therapy.

Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection.

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

P304

e95961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0095961

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261838831

http://www.w3.org/2001/XMLSchema#string

P698

24759938

http://www.w3.org/2001/XMLSchema#string

P932

3997520

http://www.w3.org/2001/XMLSchema#string